Navigation Links
Panacea Biotech To Market Anthrax Vaccine

Panacea Biotech has bagged the registration, production and marketing rights of the anti-anthrax vaccine developed by the Centre for Biotechnology in the Jawaharlal Nehru University (JNU). It is expected that the vaccine would be in the market in 3-4 months. The Company has made a milestone payment to JNU for the exclusive rights. In addition, it will pay the university a royalty on sales. However, the company is yet to make any projections on the business the vaccine is expected to generate.//

The vaccine is different from drugs such as ciprofloxacin currently being used in the treatment of anthrax. Ciprofloxacin is administered after a person has contacted anthrax. The vaccine develops immunity in the human body to anthrax bacillus. According to marketing director Rajesh, the vaccine developed by JNU is superior to the only other anti-anthrax vaccine available in the US. The vaccine in the US has a lot of toxic side- effects. The side-effect profile of this (JNU) vaccine is negligible. As anthrax has become a national emergency, the government's policy of fast-track registration will come into effect. This, in turn, will lead to a speedy commercialisation of the vaccine.


'"/>




Page: 1

Related medicine news :

1. Panacea Biotec In-Licenses FMD Vaccine
2. Panacea To Market Measles Vaccine In India
3. Websites That Offer Panacea for Eating Disorders may Be Dangerous
4. Biotechnology industry expected to grow into a three billion dollar industry by 2002
5. Biotechnology on the lead
6. Commercialization of Biotech Discoveries, An Encouragement For Researchers
7. Biotech drug causing anemia-EPREX
8. Leading Biotech Companies Are Interested In Acquisition Of Smaller Companies
9. Biologicals Transfer Proposal between US and Indian Biotechnology
10. Vical Biotech and NIH jointly develops HIV vaccine
11. Biotechnology Initiatives Planned In Hyderabad

Post Your Comments:
(Date:11/9/2009)...o late when it comes to preventing or improving a ...Take Off Pounds Sensibly), the nonprofit weight-lo... (Vocus) November 9, 2009 -- Tomorrow may be too ...abetes condition, according to TOPS Club, Inc. (Ta... support organization., , ,Diabetes is a disease i...
(Date:11/9/2009)...re/ -- Actress Mariska Hargitay and the Joyful H...y to raise awareness about the need for domestic v...building healing and wellness kits for women in cr...ne to each of the estimated 600 women currently be... violence shelters. ,, "Our goal is to shine a ...
(Date:11/9/2009).../ -- For the third consecutive year, the Barbara A...st preferred hospital for cancer care in southeast...esearch Corporation. ,, (Logo: http://www.ne..., The annual survey was conducted through an ema... 2009. Survey respondents were the primary healthc...
(Date:11/9/2009)...hoenix House , the nation,s leading non-profit al...ram, announced today its appointment of Deni Caris...zed leader in substance abuse treatment and resear..., 2010. ,, "Dr. Deni Carise is at the very fo...her work has resulted in a significant transformat...
(Date:11/9/2009)... -- At a time when the 250,000+ eligible Medicare ...ut finding affordable health insurance, they now h...The Today,s Options® Preferred Provider Organ...ost-effective and comprehensive alternative to Ori...ple with Medicare can choose to sign up for this n...
Breaking Medicine News(10 mins):Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 2Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 3Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 2Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 3Health News:Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan, Third Consecutive Year 2Health News:Phoenix House Appoints Dr. Deni Carise as Chief Clinical Officer - Internationally Recognized Leader in Substance Abuse Treatment and Research 2Health News:Phoenix House Appoints Dr. Deni Carise as Chief Clinical Officer - Internationally Recognized Leader in Substance Abuse Treatment and Research 3Health News:Maine Residents With Medicare Searching for Affordable and Innovative Insurance Have Competitive Medicare Advantage Option 2
...TEREY, Calif., Nov. 10 PARI Pharma GmbH has,succe...ials comparing its,proprietary PARI Tobramycin 100...zed Investigational eFlow Nebulizer System to TOBI...ce was,a reduction in the average inhalation time ...
...HMOND, Va., Nov. 10 According to the American,Dia...and adults in the,United States who have diabetes ... with the disease each year. In 2007, 17.5 million...rporation,(HMC), a nationally recognized leader in...
...ergists say poor access, distrust of docs behind i...10 (HealthDay News) -- Poor access to appropriate ...posing barriers to good asthma management, leading...Allergy, Asthma & Immunology (ACAAI) annual m...
... YORK, Nov. 10 TransTech Services Partners,Inc. (...s Board of,Directors elected Dr. Ranga C. Krishna ...y. Krishna is a licensed neurologist and an experi...ceutical companies perform Phase II clinical trial...
...THACA, N.Y. The American Medical Association jour... has published a new study by researchers at Corne...tal trigger for autism among genetically vulnerabl...n the areas in which children live. , "This analys...
... This release is available in French . , Dr. R...st who revolutionized the study and treatment of p...the Canadian Medical Hall of Fame. He and his four...utions to medical science and the improved health ...
Other Medicine News:Health News:PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF 2Health News:PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF 3Health News:PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF 4Health News:Health Management Corporation Incorporates Clinically Proven Care Diabetes Management Program With Programming From dLife 2Health News:Health Management Corporation Incorporates Clinically Proven Care Diabetes Management Program With Programming From dLife 3Health News:Barriers to Good Asthma Care Detailed 2Health News:Cornell researchers' study showing evidence of a major environmental trigger for autism 2Health News:Trailblazing pain pioneer Ronald Melzack to be inducted into Medical Hall of Fame 2
(Date:11/9/2009)...BOSTON, Nov. 9 PAREXEL I...ng global biopharmaceutical services provider, tod...ty capabilities for early phase clinical developme...c., which manufactures and distributes electrocard...ide. PAREXEL is using Mortara Instrument,s Surveyo...
(Date:11/8/2009)... AARP Praises House Passage of Health Care Reform ... Medicare, improve coverage for all Americans ,...-- Today the United States House of Representative...hat would strengthen Medicare for seniors and end ...millions of Americans out of affordable health cov...
(Date:11/6/2009)...BOTHELL, Wash., Nov. 6 S...ancial results for the three and nine months ended...OLR Pharma,s President and CEO, said, "We continue...2-hour ibuprofen formulation. Several potential pa...e, personnel and external resources as they evalua...
Breaking Medicine Technology:PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 2PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 3PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 4PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 5AARP Idaho Key Vote News Alert 2AARP Idaho Key Vote News Alert 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 8SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 9Heavy drinkers face significantly increased cancer risk 53516 1Heavy drinkers face significantly increased cancer risk 53516 2A super sensor for cancer and CSIs 53513 1A super sensor for cancer and CSIs 53513 2La Jolla Institute discovers novel tumor suppressor 9459 1La Jolla Institute discovers novel tumor suppressor 9459 2La Jolla Institute discovers novel tumor suppressor 9459 3
... GlaxoSmithKline,plc announced results from an int...gational non-peptide oral platelet growth,factor, ...study,showed that PROMACTA at 50-75mg once daily r... platelet counts and also,reduced bleeding in adul...c purpura (ITP). These patients had previously,rec...
...ve" May Also Affect,Alzheimer,s Risk -, WASHINGTON...tudy,suggests that treating risk factors for heart...nd diabetes, may slow the progression,of Alzheimer...t the,2nd Alzheimer,s Association International Co...DC. , Two new studies presented at the conference ...
Other Medicine Technology:Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 2Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 3Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 4Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 5Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 6Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 2Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 3Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 4Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 5Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 6Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 7
...is a self-contained, compact, easy-to-use, bedside...rks reagents, the Ichor system provides a hematolo...lus platelet aggregation within five minutes. The ...d to both an EDTA baseline and a Collagen or ADP a...
...itro diagnostic device that provides quantitative ...s and INR units. The System uses fresh capillary w...professionals at the point of care to monitor pati...apy. ,The Immedia PT System operates by a rot...
...hich includes the world's smallest dual-chamber pa...d pacemaker technology available, including the re...d only U.S. commercially approved algorithm design...ppression algorithm in the Identity pacemaker fami...
IntelliVue Information Center
Medicine Products: